The Cancer and Leukemia Group B (CALGB) Statistical Center has primary responsibility for all statistical, data management, computing, information systems, and related activities for the CALGB. Faculty and staff statisticians and data coordinators collaborate closely with study chairs, committee chairs, and other investigators on the design, conduct, analysis, and reporting of all clinical trials and other studies conducted by the CALGB. The Statistical Center has responsibility for central data quality control and database administration. All clinical data are sent to the Statistical Center for editing, verification, and entry into the official CALGB database. Scientific laboratory data are transmitted electronically and become part of the official record. Statisticians and datacoordinators from the Statistical Center are assigned to each CALGB study. They work closely with study chairs to monitor the studies and to prepare all necessary reports, analyses, and manuscripts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA033601-35
Application #
8467680
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-12-01
Project End
2014-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
35
Fiscal Year
2013
Total Cost
$4,309,956
Indirect Cost
$1,045,361
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lee, Adam M; Shi, Qian; Alberts, Steven R et al. (2016) Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 26:133-7
DeBoer, Rebecca; Koval, Gregory; Mulkey, Flora et al. (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298-306
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Hylton, Nola M; Gatsonis, Constantine A; Rosen, Mark A et al. (2016) Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 279:44-55
Atherton, Pamela J; Burger, Kelli N; Pederson, Levi D et al. (2016) Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992). Clin Trials 13:612-620
Hatch, Ace J; Sibley, Alexander B; Starr, Mark D et al. (2016) Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 5:2249-60
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
Zhang, Qiang; Freidlin, Boris; Korn, Edward L et al. (2016) Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials :
Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2016) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging :

Showing the most recent 10 out of 427 publications